Weight management - twenty30 health

GLP-1 meds from 23andMe; Better Sex on Ozempic; Rev. Al Sharpton and Dr. Steve Klasko on Equitable Access to Weight Loss Drugs.

August 18, 2024 No Comments

AT A GLANCE DNA-testing firm 23andMe gets into the hyped weight-loss market, per Modern Healthcare. The pros and cons of compounded GLP-1medications are a hot topic, writes Brock Turner at Modern Healthcare. Gina Kolata at The New York Times asks ‘…You’ve Lost Weight Taking New Obesity Drugs. What Happens if You Stop?’ The Wall Street Journal writes that patients on weight loss meds are reporting unexpected improvements to their

USPTF on Kids with Obesity; GLP-1s on Brain Diseases; Financial Incentives to Lose Weight; Novel Amylin Drug Drives 8.6% Weight Loss at 16 Weeks

June 23, 2024 No Comments

AT A GLANCE The US Preventive Services Task Force published in JAMA a Recommendation Statement on Interventions for High Body Mass Index in Children and Adolescents. Simar Bajaj at NewScientist on GLP-1s’ unexpected effects on the brain, to treat depression, anxiety, addiction and Alzheimer’s. JAMA Pediatrics publishes the impact of financial incentives on improved outcomes of a dietary intervention among 126 adolescents with severe obesity. Zealand Pharma drug petrelintide, which targets the

Nestle Frozen Foods for GLP-1 Users; Weight-Loss Drug Sales in 2033 Balloon to $150B; No Staying Power Beyond 12 Weeks; Black Americans are Left Out.

June 2, 2024 No Comments

AT A GLANCE CNN on Nestle ‘…releasing a lineup of frozen food for people on Ozempic and other GLP-1 drugs.’ Deena Beasley at Reuters reports BMO Capital Markets now estimates annual weight-loss drug sales reaching $150 billion by 2033. South Park; The End of Obesity is very good satire, and eerily realistic. Anissa Durham on STAT ‘…New obesity drugs are seemingly everywhere. Black Americans feel left out.’

Costco’s Weight Loss Program; China Develops GLP-1 Drug; Not Everyone Loses Weight on Ozempic; Weed for Weight Loss; GLP-1 For Parkinson’s

April 7, 2024 No Comments

AT A GLANCE USA Today reports ‘…Costco and its low-cost health care partner are expanding into weight-loss management…’ Reuters notes a biosimilar version of Novo Nordisk’s popular diabetes drug Ozempic has been developed in China Sumathi Reddy at The Wall Street Journal writes some people don’t lose much weight on drugs like Ozempic. Dr. Amir Ghaferi and colleagues from Wisconsin review Metabolic Surgery for Diabetes Management

Medicare Coverage for GLP-1 meds; Oprah and Weight Stigma; Vast Underusage of Bariatric Surgery; Digital Diabetes Tools not Worth It; Obesity Costs in Pennsylvania at $20B.

March 24, 2024 No Comments

AT A GLANCE The Wall Street Journal’s Peter Loftus writes ‘…Medicare Opens Door for Covering Obesity Drugs.’ From Dani Blum at The New York Times, media icon Oprah Winfrey takes on weight stigma in her ABC News Special… starting with her own. Respected bariatric surgeon Dr. Bruce Schirmer, writes in JAMA Surgery on Metabolic Bariatric Surgery – A Vastly Underused Treatment. STAT reports digital tools for diabetes management

Novo Marketing Spend Tops $1B; Obese Subjects in Clinical Trials; Social Isolation and Obesity; Preventing Muscle Mass Loss

January 28, 2024 No Comments

AT A GLANCE The UK’s Daily Mail newspaper notes Novo Nordisk ‘…has spent around $1 billion since 2018 to create the perception that sustained weight loss is only achievable by using the products.’ Scientific American questions if weight-loss drugs are sparking a risky new war on obesity? In counter to recent clinical trials, weight maintenance after stopping GLP-1 drug semaglutide may be possible, as per the Epic Research study.

LillyDirect for Zepbound; Novo bets on mRNA Drug for Obesity; WW, Noom and Ro run the ‘Obesity Games’ gauntlet; Weight Loss and Work Success.

January 7, 2024 No Comments

AT A GLANCE Eli Lilly launches LillyDirect Pharmacy Solutions, with an independent, virtual medical weight-loss clinic, to provide direct consumer access to Zepbound. Novo Nordisk is working with Omega Therapeutics, a start-up from the same stable as moderna, ‘…to develop an mRNA treatment for obesity…’ from STAT News. Rebecca Torrence at Business Insider notes ‘…only a handful of companies have what it takes to make

WeightWatchers goes all-in on GLP-1 Meds; the Year of Ozempic; Poison Control Centers increase in Calls related to Semaglutide; 63% of Older Adults want to take Meds for Obesity.

December 17, 2023 No Comments

AT A GLANCE WeightWatchers CEO Sima Sistani says we ‘…got it wrong…’ and ‘…The science has changed…’ such that WeightWatchers announced the launch of a ‘…GLP-1 Program to provide tailored behavioral support for individuals.’ ‘…Poison control centers across the US say they are seeing a steep increase in calls related to semaglutide…’ in reporting at CNN. Twin Health, a Silicon Valley startup with an AI-based dynamic model of each individual’s

Novo Nordisk’s huge windfall; employers scramble to keep a lid on rising health care spending; GI side effects of GLP-1 meds.

October 8, 2023 No Comments

Hello all, I hope everyone is having a wonderful weekend. I am back home after an intense week on the road, capped by a terrific two days at the ASMBS Weekend conference in New Orleans (where twenty30 health is a Bronze-level Corporate Council Member). It was an outstanding opportunity to connect with old friends and colleagues while making new ones

Risks of intestinal blockage, suicide and pneumonia with GLP-1 meds; racial, social and economic inequities in US obesity prevalence; Biden administration announces $8B for hunger, nutrition

October 1, 2023 No Comments

Hello Friends, Welcome to October. It has been an extraordinarily busy period here at twenty30 health; amongst many other activities and initiatives, yours’ truly has been hitting the conference circuit of late, and have had the opportunity to attend excellent events at DHNY in New York and Health Evolution in Nashville. I also had the pleasure to be engage in

Category: Weight management